We are always introducing new clinical trials across our international network. If you can’t find what you are looking for please don’t hesitate to speak to your doctor to learn more, or contact us here.
Find a trial
At Icon, we offer clinical trials across various tumour types and blood disorders, allowing patients access to new and emerging advances in treatment. Find a trial that might be suitable for you.
Use the search function below to find a clinical trial that may suit you and your cancer diagnosis
IL Believe
A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab, Standard of Care Chemotherapy, or TransCon TLR7/8 Agonist, or in Combination With Pembrolizumab and Standard of Care Chemotherapy, in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
Locations
Farrer Park
Diagnosis
Advanced solid tumours, Cervical cancer, Lung cancer, Skin cancer – melanoma
Open for recruitment
查看 Trial
BA3011-002
A Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on a PD-1/L1, EGFR, or ALK Inhibitor
Locations
Central Building (Oncology)
Diagnosis
Lung cancer
Open for recruitment
查看 Trial
BA3011-002
A Phase 2 Study of BA3011 Alone and in Combination with Nivolumab in Adult Patients with Metastatic Non-Small Cell Lung Cancer Who Had Prior Disease Progression on a PD-1/L1, EGFR, or ALK Inhibitor
Locations
Central Building (Oncology)
Diagnosis
Lung cancer
Open for recruitment
查看 Trial
DeLLphi-306
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Locations
Mount Alvernia
Diagnosis
Lung cancer
Open for recruitment
查看 Trial
pionERA Breast Cancer
A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
Locations
Gleneagles, Farrer Park
Diagnosis
Breast cancer
Open for recruitment
查看 Trial
pionERA
A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
Locations
Gleneagles, Farrer Park
Diagnosis
Breast cancer
Open for recruitment
查看 Trial
INAVO122
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Locations
Farrer Park
Diagnosis
Breast cancer
Open for recruitment
查看 Trial
CAMBRIA-1
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer
Locations
Farrer Park
Diagnosis
Breast cancer
Open for recruitment
查看 Trial
REGENERON_ R1979-ONC-1625
An open-label study to assess the anti-tumor activity and safety of REGN1979, an Anti-CD20 X Anti-CD3 bispecific antibody, in patients with relapsed or refractory follicular lymphoma
Locations
Farrer Park
Diagnosis
Lymphoma – B-cell Non Hodgkin’s
Open for recruitment
查看 Trial
INBRX-106
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Locations
Farrer Park, Mount Alvernia
Diagnosis
Advanced solid tumours
Open for recruitment
查看 Trial
Trofuse-010
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician’s Choice in Participants with HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
Locations
Mount Alvernia
Diagnosis
Breast cancer
Open for recruitment
查看 Trial
There are no clinical trials currently available